Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dora Markati

MD, MPhil


DPhil student

Education & training

Dora completed her studies in Medicine in 2016. In 2020 she was awarded her MPhil degree in Biological Science from the University of Cambridge (UK), during which she worked on the molecular mechanisms of nervous system development. Her studies were funded by the Greek State Scholarships Foundation. She has received clinical training in General Paediatrics at Chelsea and Westminster Hospital (London, UK), Addenbrooke's Hospital (Cambridge, UK), and in Neonatology at St Mary's Hospital (London, UK). Her studies are currently funded by the Alexander S. Onassis Foundation and the Department of Paediatrics of the University of Oxford.

Research

Overall, her research interest lies in drug development for rare neurogenetic conditions. Aspects of her research include: (1) the translation of preclinical discoveries into clinical applications and novel therapies, (2) the design and conduct of natural history studies and clinical trials, and (3) the discovery and validation of biomarkers using different approaches and techniques of molecular biology.

Her current research focuses on Angelman syndrome, a rare neurogenetic condition caused by molecular defects affecting the production of the ubiquitin ligase UBE3A. She has designed a Natural History Study for individuals affected by this condition, funded by the Foundation for Angelman Syndrome Therapeutics UK. Via various approaches, including proteomic analysis, she is working towards identifying UBE3A substrates and candidate biomarkers for Angelman syndrome.